Glaxosmithkline Consumer Nigeria Plc has encountered further cost increases in the second quarter that slowed down revenue improvement, BusinessDay learnt.
The percentage of the cost of sales from its revenue stood at 74.7 percent in H1’22 from 71.8 percent in H1’21.
The pharmaceutical com
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
Folake Balogun
Folake Balogun is a tech journalist covering Africa’s fast-growing digital economy with a strong focus on incisive analysis of startup trends, venture capital, and fintech innovation, while also exploring emerging technologies such as artificial intelligence and the future of connectivity by highlighting their economic and social impact.
